

Supplement table A. Factors associated with grief severity (cross-sectional analysis) and grief reassessed at follow up (longitudinal analysis) – Sensitivity analyses with MDD participants excluded

| Covariates/ Determinants of grief persistence | Cross-Sectional Analyses | | | | Longitudinal Analysis | | | |
|---|--------------------------|--------|-------|----------------|-----------------------|--------|------|----------------|
| | Grievers N=739 | | | | Grievers N=456 | | | |
| | B | 95% CI | | <i>p</i> | OR | 95% CI | | <i>p</i> |
| Gender (female) | 1.73 | 0.13 | 3.33 | 0.03 | 0.70 | 0.40 | 1.22 | 0.20 |
| Age, years | -0.04 | -0.15 | 0.06 | 0.41 | 0.99 | 0.95 | 1.03 | 0.63 |
| Social support, score | -0.21 | -0.72 | 0.30 | 0.41 | 1.16 | 0.95 | 1.42 | 0.14 |
| Who died? | | | | | | | | |
| Partner (reference), % | ref. | - | - | - | ref. | - | - | - |
| Child, % | 4.07 | 1.70 | 6.44 | 0.001 | 1.48 | 0.69 | 3.17 | 0.31 |
| Other, % | -3.49 | -5.02 | -1.96 | ≤0.0001 | 1.24 | 0.73 | 2.13 | 0.43 |
| Depressive symptoms 1*, per 1 point of score | 0.46 | 0.35 | 0.56 | ≤0.0001 | 1.02 | 0.98 | 1.05 | 0.30 |
| Education | | | | | | | | |
| High (reference) ,% | ref. | - | - | - | ref. | - | - | - |
| Middle,% | 3.01 | 0.90 | 5.13 | 0.005 | 0.81 | 0.42 | 1.56 | 0.53 |
| Primary,% | 4.59 | 1.65 | 7.53 | 0.002 | 1.63. | 0.61 | 4.36 | 0.33 |
| Activities of daily living problems, score ^c | -2.42 | -3.96 | -0.88 | 0.002 | 0.86 | 0.49 | 1.53 | 0.62 |
| Psycholeptics* use yes vs no(%) | 0.77 | -1.07 | 2.61 | 0.41 | 1.21 | 0.65 | 2.25 | 0.54 |
| Comorbidities [§] , yes vs no (%) | -0.04 | -1.46 | 1.39 | 0.96 | 1.46 | 0.91 | 2.32 | 0.11 |
| Cognitive functioning, MMSE [‡] , - score | -0.28 | -0.84 | 0.29 | 0.33 | 1.08 | 0.90 | 1.31 | 0.41 |
| Baseline value of ICG, score | - | - | - | - | 1.05 | 1.03 | 1.08 | ≤0.0001 |

*Psycholeptics includes: benzodiazepines, antidepressants, neuroleptics and anticonvulsants

§Comorbidities includes: the prevalence of myocardial infarction, heart failure, stroke, joint problems that include osteoarthritis, rheumatoid arthritis gout, back pain and ankylosing spondylitis, chronic obstructive pulmonary disease and Diabetes mellitus

‡MMSE - The Mini-mental state examination (MMSE) test for cognitive impairment

DETERMINANTS AND PREDICTORS OF GRIEF SEVERITY AND PERSISTENCE

Supplement table B. Characteristics of study participants; (responders and non-responders)

| | Responders <u>(N = 475)</u> | | Non-responders <u>(N =296)</u> | |
|--|---------------------------------------|-------|--|-------|
| Age, years (S.D.) ^b | 70.0 | (6.5) | 77.0 | (7.3) |
| Gender (female), (%) ^a | 75 | | 68 | |
| Education ^b | | | | |
| Primary (%) | 8 | | 16 | |
| Intermediate (%) | 77 | | 75 | |
| High (%) | 15 | | 9 | |
| Depressive symptoms score (S.D.) | 8.1 | (8.6) | 10.0 | (8.6) |
| Activities of daily living problems score, (S.D.) ^b | 0.8 | (6.4) | 1.0 | (5.7) |
| Social support score,(S.D.) | 9.4 | (1.3) | 9.3 | (1.5) |
| Diagnosed MDD, (%) | 4 | | 4 | |
| Who died? | | | | |
| Partner (reference), % | 52 | | 46 | |
| Child, % | 11 | | 10 | |
| Other,% | 37 | | 44 | |
| Cognitive functioning MMSE [‡] score, (S.D.) ^b | 28.3 | (1.2) | 27.9 | (1.3) |
| Psycholeptics* use, yes (%) ^a | 17 | | 24 | |
| Comorbidities [†] , present (%) ^a | 57 | | 67 | |

Note: Group comparisons were performed with χ^2 (categorical variables) or T-test (continuous variables) for independent-samples.

^aComparison of responding with non-responding participants (p<0.05).

^bComparison of responding with non-responding participants (p<0.0001).

Values are presented as means, standard deviation (S.D) or percentages (%)

*Psycholeptics includes: benzodiazepines, antidepressants, neuroleptics and anticonvulsants.

[†]Comorbidities includes: the prevalence of MI, heart failure, stroke, joint problems that include osteoarthritis, rheumatoid arthritis, gout, back pain and ankylosing spondylitis, COPD and Diabetes mellitus

[‡]MMSE - The Mini-mental state examination (MMSE) test for cognitive impairment